MELDEQ: An alternative Model for End‐Stage Liver Disease score for patients with hepatocellular carcinoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-6473|21|5|612-622

ISSN： 1527-6465

Source： LIVER TRANSPLANTATION, Vol.21, Iss.5, 2015-05, pp. : 612-622

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Delayed hepatocellular carcinoma model for end‐stage liver disease exception score improves disparity in access to liver transplant in the United States

By  

HEPATOLOGY, Vol. 61, Iss. 5, 2015-05 ,pp. : 1643-1650

John Wiley & Sons Inc

Access to resources Recommend Favorite

Interleukin-6 Polymorphisms and Gender: Relationship with the Occurrence of Hepatocellular Carcinoma in Patients with End-Stage Liver Disease

By  

Oncology, Vol. 77, Iss. 5, 2009-11 ,pp. : 304-313

Karger

Access to resources Recommend Favorite

Adding C‐reactive protein and procalcitonin to the model of end‐stage liver disease score improves mortality prediction in patients with complications of cirrhosis

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 33, Iss. 3, 2018-03 ,pp. : 726-732

John Wiley & Sons Inc

Access to resources Recommend Favorite

Keeping high model for end‐stage liver disease score liver transplantation candidates alive

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 11, 2015-11 ,pp. : 1428-1437

John Wiley & Sons Inc

Access to resources Recommend Favorite

Outcomes for liver transplant candidates listed with low model for end‐stage liver disease score

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 11, 2015-11 ,pp. : 1403-1409

John Wiley & Sons Inc

Access to resources Recommend Favorite